AnHorn Medicines 2022H1 Corporate Update and Outlook
AnHorn Medicines is a Taiwan based new drug discovery company creating novel small molecule drugs based on Targeted Protein Degradation, to specifically target and degrade disease-related proteins. We empower AI to speed up the new drug discovery in the areas of Oncology, Neurodegenerative and Anti-Aging related diseases.
“After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile to compete with competitors’ first-in-class compounds at clinical stage. We have submitted the first US patent – provisional application for the project.” said CC Lin. Ph.D., founder and CEO.
“Moving on, we anticipate finalizing the preclinical candidate selection for the Androgen Receptor degrader program by the end of the year. And there will be two indications developing in-parallel toward clinical stage. We are excited to share recent achievements at the upcoming BIO Asia-Taiwan Exhibition.” continued Dr. Lin.
AnHorn Medicines was invited by Taipei City Government to co-exhibit at BIO Asia-Taiwan Exhibition on July 28-31. Welcome to visiting us at the booth R429 for more partnering discussions.
About AnHorn Medicines
AnHorn Medicines is a new drug discovery company founded in March 2020, creating novel small molecule drugs based on Targeted Protein Degradation, to specifically target and degrade disease-related proteins. AnHorn Medicines uses its proprietary AIMCADD® platform, an AI-aided platform to design and screen for drug candidates with high potential to treat diseases, and we build partnership with international pharmaceutical companies to push the development progress further into clinical studies by a co-development strategy. We have two assets open for partnering: the Androgen Receptor degrader for two indications – Prostate cancer and Androgenetic alopecia; And the KRAS inhibitor for various mutations across cancer types. Please visit our official website for more information: www.anhornmed.com